RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

ARX788 in HER2-positive Metastatic Breast Cancer Patients

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Henan Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06663748, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Has recovered from any AE (≤ Grade 1) related to prior surgery and prior cancer treatment;

    Inclusion criterion 6

    Has received any systemic anti-tumor therapy (with the exception of endocrine therapy, with an interval of at least 7 days) within 28 days (or at least 5 half-lives) before the first use of the investigational product;

    Exclusion criterion 12

  3. ECOG Performance Status Score of 0-1;

    Inclusion criterion 8

  4. Has at least one measurable target lesion as per RECIST1.1 criteria;

    Inclusion criterion 5

  5. Breastfeeding female, or who has childbearing potential with a positive baseline pregnancy test or who is unwilling to use effective contraception during the trial;

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06663748, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 18 to 75 years old (including upper and lower limits), male or female;
  • Unresectable locally advanced, recurrent or metastatic BC;
  • Has previously received ≤ two lines of chemotherapy (excluding hormone therapy) for recurrent or metastatic BC;
  • Tissue samples determined to be HER2 positive (defined as IHC3+ or FISH+);
  • Has at least one measurable target lesion as per RECIST1.1 criteria;
  • Has recovered from any AE (≤ Grade 1) related to prior surgery and prior cancer treatment;
  • Adequate bone marrow, liver, kidney and coagulation function;
  • ECOG Performance Status Score of 0-1;
  • Voluntarily sign the informed consent, have good compliance and are willing to comply with the follow-up visit.

Exclusion Criteria:

  • Has known history to be allergic to any active ingredient or excipient of ARX788;
  • With meningeal metastases or disseminated brain metastases or active brain metastases, who need radiation, surgery or drug therapy;
  • Has pericardial effusion, pleural effusion or ascites effusion with clinical symptoms, signs or require symptomatic treatment;
  • Has interstitial lung disease requiring steroid therapy, a history of drug-induced interstitial lung disease, a history of radiation pneumonitis, or any evidence indicating clinically active interstitial lung disease;
  • Has any eye disease that require medical intervention such as keratitis, corneal diseases or active eye infection;
  • Has cardiac insufficiency;
  • Uncontrolled hypertension;
  • Has evidence of severe or uncontrollable systemic diseases;
  • Received live vaccines within 4 weeks before the first use of the investigational product or plans to receive live vaccines during the trial;
  • Breastfeeding female, or who has childbearing potential with a positive baseline pregnancy test or who is unwilling to use effective contraception during the trial;
  • Is unwilling or unable to stop wearing corneal contact lens during the trial;
  • Has received any systemic anti-tumor therapy (with the exception of endocrine therapy, with an interval of at least 7 days) within 28 days (or at least 5 half-lives) before the first use of the investigational product;
  • Has any mental or cognitive disorder that may restrict his/her understanding and execution of the informed consent form;
  • Other conditions that the Investigator considers inappropriate for participation in this trial, such as poor compliance.

Quoted from ClinicalTrials.gov, NCT06663748, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06663748, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06663748